Clinical trial
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic…
NCT05508789 · Eli Lilly and Company, Industry · Recruiting
Key facts
| NCT number | NCT05508789 |
|---|---|
| Title | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) |
| Official title | Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders |
| Intervention type | Drug |
| Interventions | Donanemab, Placebo |
| Enrollment | 1,500 |
| Start date | Oct 10, 2022 |
| Primary completion | May 1, 2028 |
| Completion | Jul 1, 2028 |
| First posted | Aug 19, 2022 |
| Last update posted | Feb 10, 2026 |
| Countries | Argentina, Australia, China, Poland, South Korea, Spain, Taiwan, United Kingdom |
At a glance
- 100–999 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: